Logo.jpg
Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer
04 nov. 2024 07h00 HE | Memo Therapeutics AG
PRESS RELEASE Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren /...
Logo.jpg
Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients
01 nov. 2024 07h00 HE | Memo Therapeutics AG
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections...
Eradivir logo
Biotech company Eradivir is developing lead drug EV25 to treat influenza
09 juil. 2024 14h24 HE | Purdue Research Foundation
WEST LAFAYETTE, Ind., July 09, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to...
Logo.jpg
Memo Therapeutics AG appoints Paul Carter as Chairperson
08 juil. 2024 07h00 HE | Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public...
Logo.jpg
Memo Therapeutics AG appoints Paul Carter as Chairperson
08 juil. 2024 02h00 HE | Memo Therapeutics AG
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and...
Logo.png
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
06 déc. 2023 08h00 HE | Cocrystal Pharma, Inc.
BOTHELL, Wash., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge...
TIP_link_300x300.jpg
Anti-Viral Therapies Market Growth ($82.92 Billion by 2028) Driven by Branded Drugs Segment during (2022-2028) – Global Report by The Insight Partners
09 mars 2023 08h46 HE | The Insight Partners
New York, March 09, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global...
logo.gif
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
28 juin 2021 08h30 HE | Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Cytovia.png
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
03 juin 2020 13h25 HE | Cytovia Therapeutics
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...
Logo.png
Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex
14 avr. 2020 11h00 HE | Guardion Health Sciences, Inc.
- acuMMUNE now available for sale in the United States through online platforms - San Diego, California, April 14, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the...